Diagnostic solutions provider QuidelOrtho Corporation (Nasdaq: QDEL) has announced it will release its second quarter financial results for the period ending June 28, 2026, after the U.S. stock market closes on August 6. Following the earnings release, the company will host a webcast conference call at 5:00 PM Eastern Time on the same day to discuss the financial outcomes.

QuidelOrtho is a leading global provider of diagnostic solutions, with operations spanning clinical chemistry, immunoassays, immunohematology, and molecular testing. In the previous quarter, the company reported revenue of $619.8 million, a year-over-year decline of 10.5%, and a net loss of $91.8 million.

When reporting first-quarter results in May, the company updated its full-year 2026 guidance. It now expects annual revenue between $2.7 billion and $2.75 billion, adjusted EBITDA in the range of $615 million to $630 million, adjusted earnings per share of $0.80 to $2.00, and free cash flow of $100 million to $120 million. During the management conference call, executives indicated that second quarter results are expected to be roughly flat sequentially, but core business operations should see year-over-year growth, with stronger performance anticipated in the second half of the year to support the annual targets.

For the second quarter, analysts' average revenue estimate is approximately $621 million, while market expectations for earnings per share vary. The market's focus remains on the growth trajectory of the company's non-respiratory diagnostics business and the progress of integrating the LEX Diagnostics acquisition.